Phase II trial of bortezomib (PS-341) and pegylated liposomal doxorubicin as initial therapy for adult patients with symptomatic multiple myeloma

Trial Profile

Phase II trial of bortezomib (PS-341) and pegylated liposomal doxorubicin as initial therapy for adult patients with symptomatic multiple myeloma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Bortezomib (Primary) ; Doxorubicin liposomal (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 28 Feb 2011 Planned End Date added to 1 Jan 2013 as reported by ClinicalTrials.gov.
    • 19 Jan 2007 Interim results have been reported.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top